)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Syndax Pharmaceuticals
Syndax Pharmaceuticals (SNDX) investor relations material
Syndax Pharmaceuticals Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary12 Feb, 2026
Financial performance and product growth
Achieved standout annual revenue with $125M in Revuforj sales and $152M in Niktimvo sales in the first 11 months on the market, both showing strong quarter-over-quarter growth.
Revuforj saw 38% growth in Q4, driven by expanded indications and increased patient penetration, especially in KMT2A and NPM1.
Maintenance therapy uptake in KMT2A patients post-transplant reached 35%-40%, with expectations to grow to 70%-80% over time.
Both products are expected to continue meaningful expansion, with significant milestones anticipated through 2026.
Operating expenses are being kept flat at $400M, supporting a clear path to profitability without additional funding needs.
Product development and clinical milestones
Revuforj is expanding into new indications, including NPM1, with strong physician awareness and anticipation for broader use.
Real-world and clinical data supporting maintenance therapy are being generated and will be presented at medical conferences in 2026.
Revuforj is being explored for myeloproliferative neoplasms (MPN), with preclinical data showing promise and clinical trials planned.
Niktimvo is approved for later-line chronic GVHD, with ongoing trials in earlier lines and combinations expected to read out in 2027 and 2028.
IPF phase II trial for axatilimab is fully enrolled, with data expected in the second half of 2026; positive results could lead to phase III development.
Market strategy and partnerships
Revuforj aims for dominant market share in both KMT2A and NPM1, leveraging best-in-class efficacy and physician education.
Niktimvo's U.S. commercialization is a 50/50 profit split with Incyte, with 25%-30% of net sales recognized as collaboration revenue.
Incyte is running key trials to expand Niktimvo's use in GVHD, including ex-U.S. markets.
Collaboration with Incyte for IPF and other indications involves shared costs (55% Incyte, 45% partner) for future trials.
Lifecycle management strategies are in place to maximize value from both franchises through new indications and global expansion.
NPM1 market share: How to achieve dominance?
IPF trial: What FVC change is needed?
KMT2A maintenance: Timeline to 70-80%?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Syndax Pharmaceuticals earnings date
Q4 20253 Mar, 2026
Syndax Pharmaceuticals
Next Syndax Pharmaceuticals earnings date
Q4 20253 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Syndax Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for cancer. The company's lead programs target immune pathways and tumor microenvironments to enhance the body’s ability to fight cancer. Syndax's pipeline includes treatments for both solid tumors and hematologic cancers, aiming to address unmet medical needs by improving outcomes for cancer patients through novel combination therapies. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage